691007-09-7
691007-09-7
Chemical Structure
Risperidone E-oxime
- CAS No.: 691007-09-7
- Formula:C23H28F2N4O2
- Molecular Weight:430.49
IUPAC Name: (E)-3-(2-(4-((2,4-difluorophenyl)(hydroxyimino)methyl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one
InChIKey: BRCINVRBDDVLDW-HPNDGRJYSA-N
SMILES: O=C1C(CCN2CCC(/C(C3=CC=C(F)C=C3F)=N\O)CC2)=C(C)N=C4N1CCCC4
Biological Activity: Risperidone E-oxime is an impurity of Risperidone[1]. Risperidone is a serotonin 5-HT2 receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist, with Kis of 4.8, 5.9 nM for 5-HT2A and dopamine D2 receptor, respectively [2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Risperidone E-oxime | 98.97% | Risperidone E-oxime is an impurity of Risperidone. Risperidone is a serotonin 5-HT2 receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist, with Kis of 4.8, 5.9 nM for 5-HT2A and dopamine D2 receptor, respectively . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Risperidone E-oxime (Standard) | ≥98% | Risperidone E-oxime (Standard) is the analytical standard of Risperidone E-oxime. This product is intended for research and analytical applications. Risperidone E-oxime is an impurity of Risperidone. Risperidone is a serotonin 5-HT2 receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist, with Kis of 4.8, 5.9 nM for 5-HT2A and dopamine D2 receptor, respectively . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pavel Slanina, et al. Process for making risperidone and intermediates therefor. US20040097523A1.
- [2]. Nyberg S, et al. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl). 1993;110(3):265-72. [Content Brief]
- [3]. Zhu HJ, et al. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology. 2007 Apr;32(4):757-64. [Content Brief]
